KOMURO Akiyoshi
Department of Medicine | Lecturer |
Last Updated :2024/11/22
■Researcher comments
List of press-related appearances
1
■Researcher basic information
Homepage URL
J-Global ID
Research Keyword
- がん幹細胞 エピジェネティクス 腫瘍生物学
■Career
Career
■Research activity information
Paper
- Masahiko Honda; Ryota Inoue; Kuniyuki Nishiyama; Takeshi Ueda; Akiyoshi Komuro; Hisayuki Amano; Ryoichi Sugisawa; Suman Dash; Jun Shirakawa; Hitoshi OkadaJournal of Cellular Physiology Wiley 0021-9541 2024/09Abstract During skeletal muscle adaptation to physiological or pathophysiological signals, contractile apparatus and mitochondrial function are coordinated to alter muscle fiber type. Although recent studies have identified various factors involved in modifying contractile proteins and mitochondrial function, the molecular mechanisms coordinating contractile and metabolic functions during muscle fiber transition are not fully understood. Using a gene‐deficient mouse approach, our previous studies uncovered that vestigial‐like family member 2 (Vgll2), a skeletal muscle‐specific transcription cofactor activated by exercise, is essential for fast‐to‐slow adaptation of skeletal muscle. The current study provides evidence that Vgll2 plays a role in increasing muscle mitochondrial mass and oxidative capacity. Transgenic Vgll2 overexpression in mice altered muscle fiber composition toward the slow type and enhanced exercise endurance, which contradicted the outcomes observed with Vgll2 deficiency. Vgll2 expression was positively correlated with the expression of genes related to mitochondrial function in skeletal muscle, mitochondrial DNA content, and protein abundance of oxidative phosphorylation complexes. Additionally, Vgll2 overexpression significantly increased the maximal respiration of isolated muscle fibers and enhanced the suppressive effects of endurance training on weight gain. Notably, no additional alteration in expression of myosin heavy chain genes was observed after exercise, suggesting that Vgll2 plays a direct role in regulating mitochondrial function, independent of its effect on contractile components. The observed increase in exercise endurance and metabolic efficiency may be attributed to the acute upregulation of genes promoting fatty acid utilization as a direct consequence of Vgll2 activation facilitated by endurance exercise. Thus, the current study establishes that Vgll2 is an integrative regulator of mitochondrial function and contractility in skeletal muscle.
- Suman Dash; Takeshi Ueda; Akiyoshi Komuro; Masahiko Honda; Ryoichi Sugisawa; Hitoshi OkadaCell death & disease 15 (2) 131 - 131 2024/02Pancreatic ductal adenocarcinoma (PDAC) is considered one of the most lethal forms of cancer. Although in the last decade, an increase in 5-year patient survival has been observed, the mortality rate remains high. As a first-line treatment for PDAC, gemcitabine alone or in combination (gemcitabine plus paclitaxel) has been used; however, drug resistance to this regimen is a growing issue. In our previous study, we reported MYC/glutamine dependency as a therapeutic target in gemcitabine-resistant PDAC secondary to deoxycytidine kinase (DCK) inactivation. Moreover, enrichment of oxidative phosphorylation (OXPHOS)-associated genes was a common property shared by PDAC cell lines, and patient clinical samples coupled with low DCK expression was also demonstrated, which implicates DCK in cancer metabolism. In this article, we reveal that the expression of most genes encoding mitochondrial complexes is remarkably upregulated in PDAC patients with low DCK expression. The DCK-knockout (DCK KO) CFPAC-1 PDAC cell line model reiterated this observation. Particularly, OXPHOS was functionally enhanced in DCK KO cells as shown by a higher oxygen consumption rate and mitochondrial ATP production. Electron microscopic observations revealed abnormal mitochondrial morphology in DCK KO cells. Furthermore, DCK inactivation exhibited reactive oxygen species (ROS) reduction accompanied with ROS-scavenging gene activation, such as SOD1 and SOD2. SOD2 inhibition in DCK KO cells clearly induced cell growth suppression. In combination with increased anti-apoptotic gene BCL2 expression in DCK KO cells, we finally reveal that venetoclax and a mitochondrial complex I inhibitor are therapeutically efficacious for DCK-inactivated CFPAC-1 cells in in vitro and xenograft models. Hence, our work provides insight into inhibition of mitochondrial metabolism as a novel therapeutic approach to overcome DCK inactivation-mediated gemcitabine resistance in PDAC patient treatment.
- 骨髄系腫瘍におけるNEDD化酵素の腫瘍抑制的な役割上田 健; Dash Suman; 本多 賢彦; 古室 暁義; 岡田 斉日本生化学会大会プログラム・講演要旨集 (公社)日本生化学会 96回 [1P - 479] 2023/10
- 網羅的CRISPRライブラリースクリーニングによるIFNγ-PD-L1経路制御因子の同定岡田 斉; Dash Suman; 本多 賢彦; 古室 暁義; 上田 健日本生化学会大会プログラム・講演要旨集 (公社)日本生化学会 96回 [1P - 493] 2023/10
- Suman Dash; Takeshi Ueda; Akiyoshi Komuro; Hisayuki Amano; Masahiko Honda; Masahito Kawazu; Hitoshi OkadaMolecular cancer research : MCR 21 (5) 444 - 457 2023/02 [Refereed]
Pancreatic ductal adenocarcinoma (PDAC) is one of the most life-threatening malignancies. Although the deoxycytidine analog gemcitabine has been used as the first-line treatment for PDAC, the primary clinical challenge arises because of an eventual acquisition of resistance. Therefore, it is crucial to elucidate the mechanisms underlying gemcitabine resistance to improve treatment efficacy. To investigate potential genes whose inactivation confers gemcitabine resistance, we performed CRISPR knockout library screening. We found that DCK deficiency is the primary mechanism of gemcitabine resistance, and the inactivation of CRYBA2, DMBX1, CROT, and CD36 slightly conferred gemcitabine resistance. In particular, gene expression analysis revealed that DCK-knockout (KO) cells displayed a significant enrichment of genes associated with MYC targets, folate/one-carbon metabolism and glutamine metabolism pathways. Evidently, chemically targeting each of these pathways significantly reduced the survival of DCK KO cells. Moreover, the pathways enriched in DCK KO cells represented a trend similar to those in PDAC cell lines and samples of patients with PDAC with low DCK expression. We further observed that short-term treatment of parental CFPAC-1 cells with gemcitabine induces the expression of several genes, which promote synthesis and transport of glutamine in a dose-dependent manner, which suggests glutamine availability as a potential mechanism of escaping drug toxicity in an initial response for survival. Thus, our findings provide insights into novel therapeutic approaches for gemcitabine-resistant PDAC and emphasize the involvement of glutamine metabolism in drug-tolerant persister cells. Implications: Our study revealed the key pathways involved in gemcitabine resistance in PDAC, thus providing potential therapeutic strategies. - 骨髄球系細胞の形質転換におけるタンパク質NEDD化制御異常の役割上田 健; ダッシュ・スーマン; 本多 賢彦; 古室 暁義; 岡田 斉日本生化学会大会プログラム・講演要旨集 (公社)日本生化学会 95回 1P - 291 2022/11
- 遺伝子改変マウスを用いたVgII2発現量が及ぼす筋代謝への影響の解析本多 賢彦; Dash Suman; 古室 暁義; 上田 健; 岡田 斉日本生化学会大会プログラム・講演要旨集 (公社)日本生化学会 95回 3P - 230 2022/11
- Ryo Tanabe; Kohei Miyazono; Tomoki Todo; Nobuhito Saito; Caname Iwata; Akiyoshi Komuro; Satoshi Sakai; Erna Raja; Daizo Koinuma; Masato Morikawa; Bengt Westermark; Carl-Henrik HeldinMolecular oncology 16 (1) 269 - 288 2021/07 [Refereed]
Glioma-initiating cells (GICs), a major source of glioblastoma recurrence, are characterized by the expression of neural stem cell markers and the ability to grow by forming nonadherent spheres under serum-free conditions. Bone morphogenetic proteins (BMPs), members of the transforming growth factor-β family, induce differentiation of GICs and suppress their tumorigenicity. However, the mechanisms underlying the BMP-induced loss of GIC stemness have not been fully elucidated. Here, we show that paired related homeobox 1 (PRRX1) induced by BMPs decreases the CD133-positive GIC population and inhibits tumorigenic activity of GICs in vivo. Of the two splice isoforms of PRRX1, the longer isoform, pmx-1b, but not the shorter isoform, pmx-1a, induces GIC differentiation. Upon BMP stimulation, pmx-1b interacts with the DNA methyltransferase DNMT3A and induces promoter methylation of the PROM1 gene encoding CD133. Silencing DNMT3A maintains PROM1 expression and increases the CD133-positive GIC population. Thus, pmx-1b promotes loss of stem cell-like properties of GICs through region-specific epigenetic regulation of CD133 expression by recruiting DNMT3A, which is associated with decreased tumorigenicity of GICs. - KDM4B promotes acute myeloid leukemia associated with AML1-ETO by regulating chromatin accessibilityTakeshi Ueda; Akinori Kanai; Akiyoshi Komuro; Hisayuki Amano; Kazushige Ota; Masahiko Honda; Masahito Kawazu; Hitoshi OkadaFASEB BioAdvances 2021 [Refereed]
Epigenetic alterations of chromatin structure affect chromatin accessibility and collaborate with genetic alterations in the development of cancer. Lysine demethylase 4B (KDM4B) has been identified as a JmjC domain-containing epigenetic modifier that possesses histone demethylase activity. Although recent studies have demonstrated that KDM4B positively regulates the pathogenesis of multiple types of solid tumors, the tissue specificity and context dependency have not been fully elucidated. In this study, we investigated gene expression profiles established from clinical samples and found that KDM4B is elevated specifically in acute myeloid leukemia (AML) associated with chromosomal translocation 8;21 [t(8;21)], which results in a fusion of the AML1 and the eight-twenty-one (ETO) genes to generate a leukemia oncogene, AML1-ETO fusion transcription factor. Short hairpin RNA-mediated KDM4B silencing significantly reduced cell proliferation in t(8;21)-positive AML cell lines. Meanwhile, KDM4B silencing suppressed the expression of AML1-ETO-inducible genes, and consistently perturbed chromatin accessibility of AML1-ETO-binding sites involving altered active enhancer marks and functional cis-regulatory elements. Notably, transduction of murine KDM4B orthologue mutants followed by KDM4B silencing demonstrated a requirement of methylated-histone binding modules for a proliferative surge. To address the role of KDM4B in leukemia development, we further generated and analyzed Kdm4b conditional knockout mice. As a result, Kdm4b deficiency attenuated clonogenic potential mediated by AML1-ETO and delayed leukemia progression in vivo. Thus, our results highlight a tumor-promoting role of KDM4B in AML associated with t(8;21). - ヒストン脱メチル化酵素UTXの機能阻害による乳がん悪性化への影響古室 暁義; 上田 健; 岡田 斉日本癌学会総会記事 (一社)日本癌学会 79回 PJ9 - 7 0546-0476 2020/10
- Naohiro Oka; Akiyoshi Komuro; Hisayuki Amano; Suman Dash; Masahiko Honda; Kazushige Ota; Shunji Nishimura; Takeshi Ueda; Masao Akagi; Hitoshi OkadaPharmacology research & perspectives 8 (4) e00632 2020/08 [Refereed]
Osteosarcoma (OS) is the most common malignant bone tumor and a leading cause of cancer-related deaths in children and adolescents. Current standard treatments for OS are a combination of preoperative chemotherapy, surgical resection, and adjuvant chemotherapy. Cisplatin is used as the standard chemotherapeutic for OS treatment, but it induces various adverse effects, limiting its clinical application. Improving treatment efficacy without increasing the cisplatin dosage is desirable. In the present study, we assessed the combined effect of ascorbate on cisplatin treatment using cultured human OS cells. Co-treatment with ascorbate induced greater suppression of OS cell but not nonmalignant cell proliferation. The chemosensitizing effect of ascorbate on cisplatin treatment was tightly linked to ROS production. Altered cellular redox state due to increased ROS production modified glycolysis and mitochondrial function in OS cells. In addition, OS cell sphere formation was markedly decreased, suggesting that ascorbate increased the treatment efficacy of cisplatin against stem-like cells in the cancer cell population. We also found that enhanced MYC signaling, ribosomal biogenesis, glycolysis, and mitochondrial respiration are key signatures in OS cells with cisplatin resistance. Furthermore, cisplatin resistance was reversed by ascorbate. Taken together, our findings provide a rationale for combining cisplatin with ascorbate in therapeutic strategies against OS. - 岡 尚宏; 天野 恭志; 古室 暁義; 太田 一成; 上田 健; 橋本 和彦; 西村 俊司; 岡田 斉; 赤木 將男日本整形外科学会雑誌 (公社)日本整形外科学会 94 (6) S1523 - S1523 0021-5325 2020/07
- 骨肉腫におけるシスプラチンと抗酸化物質によるROS産生を介した抗腫瘍効果の検討岡 尚宏; 天野 恭志; 古室 暁義; 太田 一成; 上田 健; 橋本 和彦; 西村 俊司; 岡田 斉; 赤木 將男日本整形外科学会雑誌 (公社)日本整形外科学会 94 (6) S1523 - S1523 0021-5325 2020/07
- 本多 賢彦; 上田 健; 古室 暁義; 天野 恭志; 岡田 斉近畿大学医学雑誌 近畿大学医学会 44 (3-4) 17A - 17A 0385-8367 2019/12
- ヒストン脱メチル化酵素KDM6Aの機能阻害は乳がん悪性化を促進する(Inhibition of histone demethylase KDM6A promotes breast cancer progression)古室 暁義; 上田 健; 岡田 斉日本癌学会総会記事 日本癌学会 78回 E - 2084 0546-0476 2019/09
- Kazushige Ota; Akiyoshi Komuro; Hisayuki Amano; Akinori Kanai; Kai Ge; Takeshi Ueda; Hitoshi OkadaScientific reports 9 (1) 10036 - 10036 2019/07 [Refereed]
Obesity increases the risk of metabolic disorders like diabetes mellitus and dyslipidemia. However, how metabolic status is sensed and regulates cellular behavior is unclear. Utx is an H3K27 demethylase that influences adipocyte function in vitro. To examine its role in vivo, we generated mice lacking Utx in adipocytes (UtxAKO). Although all UtxAKO mice grew normally on a normal chow diet (NCD), female UtxAKO mice on a high fat diet (HFD) showed striking reductions in body fat compared to control mice (Ctrl). Gene expression profiling of adipose tissues of HFD-fed UtxAKO female mice revealed decreased expression of rate-limiting enzymes of triacylglycerol synthesis but increased expression of those of cholesterol/steroid hormone synthesis. Moreover, these animals resisted adiposity induced by ovariectomy and exhibited increased estrogen in visceral adipose tissues. Thus, upon HFD feeding, Utx regulates lipid metabolism in adipose tissues by influencing the local hormonal microenvironment. Conversely, Utx deficiency skews lipid catabolism to enhance cholesterol/steroid hormone production and repress obesity. - Akiyoshi Komuro; Erna Raja; Caname Iwata; Manabu Soda; Kazunobu Isogaya; Keiko Yuki; Yasushi Ino; Masato Morikawa; Tomoki Todo; Hiroyuki Aburatani; Hiromichi Suzuki; Melissa Ranjit; Atsushi Natsume; Akitake Mukasa; Nobuhito Saito; Hitoshi Okada; Hiroyuki Mano; Kohei Miyazono; Daizo KoinumaInternational journal of cancer 142 (8) 1627 - 1639 2018/04 [Refereed]
Glioblastoma is one of the most malignant forms of cancer, for which no effective targeted therapy has been found. Although The Cancer Genome Atlas has provided a list of fusion genes in glioblastoma, their role in progression of glioblastoma remains largely unknown. To search for novel fusion genes, we obtained RNA-seq data from TGS-01 human glioma-initiating cells, and identified a novel fusion gene (HMGA2-EGFR), encoding a protein comprising the N-terminal region of the high-mobility group AT-hook protein 2 (HMGA2) fused to the C-terminal region of epidermal growth factor receptor (EGFR), which retained the transmembrane and kinase domains of the EGFR. This fusion gene product showed transforming potential and a high tumor-forming capacity in cell culture and in vivo. Mechanistically, HMGA2-EGFR constitutively induced a higher level of phosphorylated STAT5B than EGFRvIII, an in-frame exon deletion product of the EGFR gene that is commonly found in primary glioblastoma. Forced expression of HMGA2-EGFR enhanced orthotopic tumor formation of the U87MG human glioma cell line. Furthermore, the EGFR kinase inhibitor erlotinib blocked sphere formation of TGS-01 cells in culture and inhibited tumor formation in vivo. These findings suggest that, in addition to gene amplification and in-frame exon deletion, EGFR signaling can also be activated by gene fusion, suggesting a possible avenue for treatment of glioblastoma. - E. Raja; A. Komuro; R. Tanabe; S. Sakai; Y. Ino; N. Saito; T. Todo; M. Morikawa; H. Aburatani; D. Koinuma; C. Iwata; K. MiyazonoONCOGENE NATURE PUBLISHING GROUP 36 (35) 4963 - 4974 0950-9232 2017/08 [Refereed]
Bone morphogenetic protein (BMP) signaling exerts antitumor activities in glioblastoma; however, its precise mechanisms remain to be elucidated. Here, we demonstrated that the BMP type I receptor ALK-2 (encoded by the ACVR1 gene) has crucial roles in apoptosis induction of patient-derived glioma-initiating cells (GICs), TGS-01 and TGS-04. We also characterized a BMP target gene, Distal-less homeobox 2 (DLX2), and found that DLX2 promoted apoptosis and neural differentiation of GICs. The tumor-suppressive effects of ALK-2 and DLX2 were further confirmed in a mouse orthotopic transplantation model. Interestingly, valproic acid (VPA), an anti-epileptic compound, induced BMP2, BMP4, ACVR1 and DLX2 mRNA expression with a concomitant increase in phosphorylation of Smad1/5. Consistently, we showed that treatment with VPA induced apoptosis of GICs, whereas silencing of ALK-2 or DLX2 expression partially suppressed it. Our study thus reveals BMP-mediated inhibitory mechanisms for glioblastoma, which explains, at least in part, the therapeutic effects of VPA. - Kazushige Ota; Kit I. Tong; Kouichiro Goto; Shuta Tomida; Akiyoshi Komuro; Zhong Wang; Kazuto Nishio; Hitoshi OkadaPLOS ONE PUBLIC LIBRARY SCIENCE 12 (3) e0173713 1932-6203 2017/03 [Refereed]
Understanding the molecular mechanisms that drive adipogenesis is important in developing new treatments for obesity and diabetes. Epigenetic regulations determine the capacity of adipogenesis. In this study, we examined the role of a histone H3 lysine 27 demethylase, the ubiquitously transcribed tetratricopeptide repeat protein on the X chromosome (Utx), in the differentiation of mouse embryonic stem cells (mESCs) to adipocytes. Using gene trapping, we examined Utx-deficient male mESCs to determine whether loss of Utx would enhance or inhibit the differentiation of mESCs to adipocytes. Utx-deficient mESCs showed diminished potential to differentiate to adipocytes compared to that of controls. In contrast, Utx-deficient preadipocytes showed enhanced differentiation to adipocytes. Microarray analyses indicated that the beta-catenin/c-Myc signaling pathway was differentially regulated in Utx-deficient cells during adipocyte differentiation. Therefore, our data suggest that Utx governs adipogenesis by regulating c-Myc in a differentiation stage-specific manner and that targeting the Utx signaling pathway could be beneficial for the treatment of obesity, diabetes, and congenital utx-deficiency disorders. - Kit I. Tong; Kazushige Ota; Akiyoshi Komuro; Takeshi Ueda; Akihiko Ito; C. Anne Koch; Hitoshi OkadaCELL DEATH & DISEASE NATURE PUBLISHING GROUP 7 (10) e2401 2041-4889 2016/10 [Refereed]
Therapy-related cancers are potentially fatal late life complications for patients who received radio-or chemotherapy. So far, the mouse model showing reduction or delay of these diseases has not been described. We found that the disruption of Aplf in mice moderately attenuated DNA damage repair and, unexpectedly, impeded myeloid neoplasms after exposure to ionizing radiation (IR). Irradiated mutant mice showed higher rates of p53-dependent cell death, fewer chromosomal translocations, and a delay in malignancy-induced mortality. Simultaneous deficiency of p53 abrogated IR-induced apoptosis and the benefit of impaired DNA repair on mortality in irradiated Aplf(-/-) mice. Depletion of APLF in non-tumorigenic human cells also markedly reduced the risk of radiation-induced chromosomal aberrations. We therefore conclude that proficient DNA damage repair may promote chromosomal aberrations in normal tissues after irradiation and induce malignant evolution, thus illustrating the potential benefit in sensitizing p53 function by manipulating DNA repair efficiency in cancer patients undergoing genotoxic therapies. - 膠芽腫における新規融合遺伝子HMGA2-EGFRの同定古室 暁義; 岩田 要; 曽田 学; 磯谷 一暢; 稲生 靖; 藤堂 具紀; 油谷 浩幸; 夏目 敦至; 武笠 晃丈; 斉藤 延人; 間野 博行; 宮園 浩平; 鯉沼 代造日本生化学会大会・日本分子生物学会年会合同大会講演要旨集 (公社)日本生化学会 88回・38回 [2P1111] - [2P1111] 2015/12
- K. C. Kawabata; S. Ehata; A. Komuro; K. Takeuchi; K. MiyazonoONCOGENE NATURE PUBLISHING GROUP 32 (16) 2096 - 2106 0950-9232 2013/04 [Refereed]
Transforming growth factor-beta (TGF-beta) exhibits growth inhibitory effects on various types of tumor cells, including B-cell lymphoma cells. In the present study, the role of TGF-beta in the survival of Epstein-Barr virus-negative B-cell lymphoma Ramos cells was investigated. As TGF-beta-induced apoptosis of Ramos cells in vitro and in vivo, we attempted to identify novel target gene(s) responsible for their survival. Oligonucleotide microarray analysis and chromatin immunoprecipitation revealed that Smad proteins directly regulated the transcription of membrane-spanning 4-domains, subfamily A, member 1 (MS4A1), also known as CD20, in Ramos cells upon TGF-beta stimulation. In addition, immunohistochemical analysis using clinical samples from B-cell lymphoma patients showed an inverse correlation between the expression of MS4A1/CD20 and phosphorylation of Smad3. Although knockdown of MS4A1/CD20 in Ramos cells resulted in an increase of apoptotic cells, Ramos cells stably expressing MS4A1/CD20 were resistant to TGF-beta-induced apoptosis. This suggests that MS4A1/CD20 is responsible for TGF-beta-induced apoptosis of B-cell lymphoma cells. Moreover, downregulation of MS4A1/CD20 by TGF-beta attenuated the effects of the monoclonal anti-MS4A1/CD20 antibody, rituximab, on Ramos cells. Our findings suggest that the sensitivity of B-cell lymphoma cells to rituximab may be affected by TGF-beta signaling. Oncogene (2013) 32, 2096-2106; doi:10.1038/onc.2012.219; published online 4 June 2012 - S. Ehata; E. Johansson; R. Katayama; S. Koike; A. Watanabe; Y. Hoshino; Y. Katsuno; A. Komuro; D. Koinuma; M. R. Kano; M. Yashiro; K. Hirakawa; H. Aburatani; N. Fujita; K. MiyazonoONCOGENE NATURE PUBLISHING GROUP 30 (14) 1693 - 1705 0950-9232 2011/04 [Refereed]
Stem cells in normal tissues and cancer-initiating cells (CICs) are known to be enriched in side population (SP) cells. However, the factors responsible for the regulation of expression of ABCG2, involved in efflux of dyes, in SP cells have not been fully investigated. Here, we characterized the SP cells within diffuse-type gastric carcinoma, and examined the effects of transforming growth factor-beta (TGF-beta) on SP cells. Diffuse-type gastric carcinoma cells established from four independent patients universally contained SP cells between 1 and 4% of total cells, which displayed greater tumorigenicity than non-SP cells did. TGF-beta repressed the transcription of ABCG2 through direct binding of Smad2/3 to its promoter/enhancer, and the number of SP cells and the tumor-forming ability of cancer cells were decreased by TGF-beta, although ABCG2 is not directly involved in the tumor-forming ability of SP cells. Cancer cells from metastatic site expressed much higher levels of ABCG2 and included a greater percentage of SP cells than parental cancer cells did. SP cells are thus responsible for the progression of diffuse-type gastric carcinoma, and TGF-beta negatively contributes to maintain the CICs within the cancer. Oncogene (2011) 30, 1693-1705; doi:10.1038/onc.2010.546; published online 6 December 2010 - Erik Johansson; Akiyoshi Komuro; Caname Iwata; Akifumi Hagiwara; Yuma Fuse; Akira Watanabe; Yasuyuki Morishita; Hiroyuki Aburatani; Keiko Funa; Mitsunobu R. Kano; Kohei MiyazonoCANCER SCIENCE WILEY-BLACKWELL 101 (11) 2398 - 2403 1347-9032 2010/11 [Refereed]
Diffuse-type gastric carcinoma is characterized by rapid progression and poor prognosis. High expression of transforming growth factor (TGF)-beta and thick stromal fibrosis are observed in this type of gastric carcinoma. We have previously shown that disruption of TGF-beta signaling via introduction of a dominant negative form of the TGF-beta type II receptor (dnT beta RII) into diffuse-type gastric cancer cell lines, including OCUM-2MLN, caused accelerated tumor growth through induction of tumor angiogenesis in vivo. In the present study, we show that TGF-beta induces upregulation of expression of tissue inhibitor of metalloproteinase 2 (TIMP2) in the OCUM-2MLN cell line in vitro, and that expression of TIMP2 is repressed by dnT beta RII expression in vivo. Transplantation of the OCUM-2MLN cells to nude mice exhibited accelerated tumor growth in response to dnT beta RII expression, which was completely abolished when TIMP2 was coexpressed with dnT beta RII. Although the blood vessel density of TIMP2-expressing tumors was only slightly decreased, the degree of hypoxia in tumor tissues was significantly increased and pericytes covering tumor vasculature were decreased by TIMP2 expression in OCUM-2MLN cells, suggesting that the function of tumor vasculatures was repressed by TIMP2 and consequently tumor growth was reduced. These findings provide evidence that one of the mechanisms of the increase in angiogenesis in diffuse-type gastric carcinoma is the downregulation of the anti-angiogenic protein TIMP2. (Cancer Sci 2010; 101: 2398-2403). - Erik Johansson; Akiyoshi Komuro; Caname Iwata; Akifumi Hagiwara; Yuma Fuse; Akira Watanabe; Yasuyuki Morishita; Hiroyuki Aburatani; Keiko Funa; Mitsunobu R. Kano; Kohei MiyazonoInternational Journal of Psychoanalysis 91 (5) 2398 - 2403 0020-7578 2010/10 [Refereed]
Diffuse-type gastric carcinoma is characterized by rapid progression and poor prognosis. High expression of transforming growth factor (TGF)-β and thick stromal fibrosis are observed in this type of gastric carcinoma. We have previously shown that disruption of TGF-β signaling via introduction of a dominant negative form of the TGF-β type II receptor (dnTβRII) into diffuse-type gastric cancer cell lines, including OCUM-2MLN, caused accelerated tumor growth through induction of tumor angiogenesis in vivo. In the present study, we show that TGF-β induces upregulation of expression of tissue inhibitor of metalloproteinase 2 (TIMP2) in the OCUM-2MLN cell line in vitro, and that expression of TIMP2 is repressed by dnTβRII expression in vivo. Transplantation of the OCUM-2MLN cells to nude mice exhibited accelerated tumor growth in response to dnTβRII expression, which was completely abolished when TIMP2 was coexpressed with dnTβRII. Although the blood vessel density of TIMP2-expressing tumors was only slightly decreased, the degree of hypoxia in tumor tissues was significantly increased and pericytes covering tumor vasculature were decreased by TIMP2 expression in OCUM-2MLN cells, suggesting that the function of tumor vasculatures was repressed by TIMP2 and consequently tumor growth was reduced. These findings provide evidence that one of the mechanisms of the increase in angiogenesis in diffuse-type gastric carcinoma is the downregulation of the anti-angiogenic protein TIMP2. (Cancer Sci 2010 101: 2398-2403) © 2010 Japanese Cancer Association. - Kunihiko Kiyono; Hiroshi I. Suzuki; Hironori Matsuyama; Yasuyuki Morishita; Akiyoshi Komuro; Mitsunobu R. Kano; Koichi Sugimoto; Kohei MiyazonoCANCER RESEARCH AMER ASSOC CANCER RESEARCH 69 (23) 8844 - 8852 0008-5472 2009/12 [Refereed]
Transforming growth factor-beta (TGF-beta) is a multifunctional cytokine that regulates cell growth, differentiation, and apoptosis of various types of cells. Autophagy is emerging as a critical response of normal and cancer cells to environmental changes, but the relationship between TGF-beta signaling and autophagy has been poorly understood. Here, we showed that TGF-beta activates autophagy in human hepatocellular carcinoma cell tines. TGF-beta induced accumulation of autophagosomes and conversion of microtubule-associated protein I light chain 3 and enhanced the degradation rate of long-lived proteins. TGF-beta increased the mRNA expression levels of BECLIN1, ATG5, ATG7, and death-associated protein kinase (DAPK). Knockdown of Smad2/3, Smad4, or DAPK, or inhibition of c-Jun NH(2)-terminal kinase, attenuated TGF-beta-induced autophagy, indicating the involvement of both Smad and non-Smad pathway(s). TGF-beta activated autophagy earlier than execution of apoptosis (6-12 versus 48 h), and reduction of autophagy genes by small interfering RNA attenuated TGF-beta-mediated growth inhibition and induction of proapoptotic genes Bim and Bmf, suggesting the contribution of autophagy pathway to the growth-inhibitory effect of TGF-beta. Additionally, TGF-beta also induced autophagy in some mammary carcinoma cells, including MDA-MB-231 cells. These findings show that TGF-beta signaling pathway activates autophagy in certain human cancer cells and that induction of autophagy is a novel aspect of biological functions of TGF-beta. [Cancer Res 2009;69(23):8844-52] - Kunihiko Kiyono; Hiroshi I. Suzuki; Yasuyuki Morishita; Akiyoshi Komuro; Caname Iwata; Masakazu Yashiro; Kosei Hirakawa; Mitsunobu R. Kano; Kohei MiyazonoCANCER SCIENCE WILEY-BLACKWELL PUBLISHING, INC 100 (10) 1809 - 1816 1347-9032 2009/10 [Refereed]
c-Ski, originally identified as a proto-oncogene product, is an important negative regulator of transforming growth factor (TGF)-beta family signaling through interaction with Smad2, Smad3, and Smad4. High expression of c-Ski has been found in some cancers, including gastric cancer. We previously showed that disruption of TGF-beta signaling by dominant-negative TGF-beta type II receptor in a diffuse-type gastric carcinoma model accelerated tumor growth through induction of tumor angiogenesis by decreased expression of the anti-angiogenic factor thrombospondin (TSP)-1. Here, we examined the function of c-Ski in human diffuse-type gastric carcinoma OCUM-2MLN cells. Overexpression of c-Ski inhibited TGF-beta signaling in OCUM-2MLN cells. Interestingly, c-Ski overexpression resulted in extensive acceleration of the growth of subcutaneous xenografts in BALB/c nu/nu female mice (6 weeks of age). Similar to tumors expressing dominant-negative TGF-beta type II receptor, histochemical studies revealed less fibrosis and increased angiogenesis in xenografted tumors expressing c-Ski compared to control tumors. Induction of TSP-1 mRNA by TGF-beta was attenuated by c-Ski in vitro, and expression of TSP-1 mRNA was decreased in tumors expressing c-Ski in vivo. These findings suggest that c-Ski overexpression promotes the growth of diffuse-type gastric carcinoma through induction of angiogenesis. (Cancer Sci 2009; 100: 1809-1816). - Akiyoshi Komuro; Masakazu Yashiro; Caname Iwata; Yasuyuki Morishita; Erik Johansson; Yoshiko Matsumoto; Akira Watanabe; Hiroyuki Aburatani; Hiroyuki Miyoshi; Kunihiko Kiyono; Yo-taro Shirai; Hiroshi I. Suzuki; Kosei Hirakawa; Mitsunobu R. Kano; Kohei MiyazonoJOURNAL OF THE NATIONAL CANCER INSTITUTE OXFORD UNIV PRESS INC 101 (8) 592 - 604 0027-8874 2009/04 [Refereed]
Diffuse-type gastric carcinoma is a cancer with poor prognosis that has high levels of transforming growth factor beta (TGF-beta) expression and thick stromal fibrosis. However, the association of TGF-beta signaling with diffuse-type gastric carcinoma has not been investigated in detail. We used a lentiviral infection system to express a dominant-negative TGF-beta type II receptor (dnT beta RII) or green fluorescent protein (GFP) as a control in the diffuse-type gastric carcinoma cell lines, OCUM-2MLN and OCUM-12. These infected cells and the corresponding parental control cells were subcutaneously or orthotopically injected into nude mice. Angiogenesis was inhibited by infecting cells with a lentivirus carrying the gene for angiogenic inhibitor thrombospondin-1 or by injecting mice intraperitoneally with the small-molecule angiogenic inhibitor sorafenib or with anti-vascular endothelial growth factor (VEGF) neutralizing antibody (six or eight mice per group). Expression of phospho-Smad2 and thrombospondin-1 was investigated immunologically in human gastric carcinoma tissues from 102 patients. All statistical tests were two-sided. Expression of dnT beta RII into OCUM-2MLN cells did not affect their proliferation in vitro, but it accelerated the growth of subcutaneously or orthotopically transplanted tumors in vivo (eg, for mean volume of subcutaneous tumors on day 10 relative to that on day 0: dnT beta RII tumors = 3.49 and GFP tumors = 2.46, difference = 1.02, 95% confidence interval [CI] = 0.21 to 1.84; P = .003). The tumors expressing dnT beta RII had higher levels of angiogenesis than those expressing GFP because of decreased thrombospondin-1 production. Similar results were obtained with OCUM-12 cells. Expression of thrombospondin-1 in the dnT beta RII tumor or treatment with sorafenib or anti-VEGF antibody reduced tumor growth, whereas knockdown of thrombospondin-1 expression resulted in more accelerated growth of OCUM-2MLN tumors than of GFP tumors (eg, mean tumor volumes on day 14 relative to those on day 0: thrombospondin-1-knockdown tumors = 4.91 and GFP tumors = 3.79, difference = 1.12, 95% CI = 0.80 to 1.44; P < .001). Positive association between phosphorylated Smad2 and thrombospondin-1 immunostaining was observed in human gastric carcinoma tissues. Disruption of TGF-beta signaling in diffuse-type gastric carcinoma models appeared to accelerate tumor growth, apparently through increased tumor angiogenesis that was induced by decreased expression of thrombospondin-1. - Hiroaki Ikushima; Akiyoshi Komuro; Kazunobu Isogaya; Masahiko Shinozaki; Ulf Hellman; Keiji Miyazawa; Kohei MiyazonoEMBO JOURNAL NATURE PUBLISHING GROUP 27 (22) 2955 - 2965 0261-4189 2008/11 [Refereed]
Transforming growth factor (TGF)-beta induces various cellular responses principally through Smad-dependent transcriptional regulation. Activated Smad complexes cooperate with transcription factors in regulating a group of target genes. The target genes controlled by the same Smad-cofactor complexes are denoted a synexpression group. We found that an Id-like helix-loop-helix protein, human homologue of Maid (HHM), is a synexpression group-restricted regulator of TGF-beta signalling. HHM suppressed TGF-beta-induced growth inhibition and cell migration but not epithelial-mesenchymal transition. In addition, HHM inhibited TGF-beta-induced expression of plasminogen activator inhibitor-type 1 (PAI-1), PDGF-B, and p21(WAF), but not Snail. We identified a basic-helix-loop-helix protein, Olig1, as one of the Smad-binding transcription factors affected by HHM. Olig1 interacted with Smad2/3 in response to TGF-beta stimulation, and was involved in transcriptional activation of PAI-1 and PDGF-B. HHM, but not Id proteins, inhibited TGF-beta signalling-dependent association of Olig1 with Smad2/3 through physical interaction with Olig1. HHM thus appears to regulate a subset of TGF-beta target genes including the Olig1-Smad synexpression group. HHM is the first example of a cellular response-selective regulator of TGF-beta signalling with clearly determined mechanisms. - ケモカイン、サイトカインと癌 Id様分子HHMはTGF-βシグナル伝達の共発現群制限の制御因子である(Chemokine, Cytokine and Cancer An Id-like molecule, HHM, is a synexpression group-restricted regulator of TGF-β signaling)生島 弘彬; 古室 暁義; 磯谷 一暢; 篠崎 正彦; 宮澤 恵二; 宮園 浩平日本癌学会総会記事 (一社)日本癌学会 67回 43 - 43 0546-0476 2008/09
- Masako Oka; Caname Iwata; Hiroshi I. Suzuki; Kunihiko Kiyono; Yasuyuki Morishita; Tetsuro Watabe; Akiyoshi Kornuro; Mitsunobu R. Kano; Kohei MiyazonoBLOOD AMER SOC HEMATOLOGY 111 (9) 4571 - 4579 0006-4971 2008/05 [Refereed]
Lymphangiogenesis is induced by various growth factors, including VEGF-C. Although TGF-beta plays crucial roles in angiogenesis, the roles of TGF-beta signaling in lymphangiogenesis are unknown. We show here that TGF-beta transduced signals in human dermal lymphatic microvascular endothelial cells (HDLECs) and inhibited the proliferation, cord formation, and migration toward VEGF-C of HDLECs. Expression of lymphatic endothelial cell (LEC) markers, including LYVE-1 and Prox1 in HDLECs, as well as early lymph vessel development in mouse embryonic stem cells in the presence of VEGF-A and C, were repressed by TGF-beta but were induced by TGF-beta type I receptor (T beta R-I) inhibitor. Moreover, inhibition of endogenous TGF-beta signaling by T beta R-I inhibitor accelerated lymphangiogenesis in a mouse model of chronic peritonitis. Lymphanglogenesis was also induced by T beta R-I inhibitor in the presence of VEGF-C in pancreatic adenocarcinoma xenograft models inoculated in nude mice. These findings suggest that TGF-beta transduces signals in LECs and plays an important role in the regulation of lymphangiogenesis in vivo. - Caname Iwata; Mitsunobu R. Kano; Akiyoshi Komuro; Masako Oka; Kunihiko Kiyono; Erik Johansson; Yasuyuki Morishita; Masakazu Yashiro; Kosei Hirakawa; Michio Kaminishi; Kohei MiyazonoCANCER RESEARCH AMER ASSOC CANCER RESEARCH 67 (21) 10181 - 10189 0008-5472 2007/11 [Refereed]
Cyclooxygenase-2 (COX-2) inhibitor has been reported to suppress tumor progression. However, it is unclear whether this inhibitor can also prevent lymphatic metastasis. To determine the effects of COX-2 inhibitor on lymphatic metastasis, etodolac, a COX-2 inhibitor, was given p.o. to mice bearing orthotopic xenografts or with carcinomatous peritonitis induced with a highly metastatic human diffuse-type gastric carcinoma cell line, OCUM-2MLN. Tumor lymphangiogenesis was significantly decreased in etodolac-treated mice compared with control mice. Consistent with this decrease in lymphangiogenesis, the total weight of metastatic lymph nodes was less in etodolac-treated mice than in control mice. Immunohistochemical analysis revealed that the major source of vascular endothelial growth factor-C (VEGF-C) and VEGF-D was F4/80-positive macrophages in our models. The mRNA levels of VEGF-C in mouse macrophage-like RAW264.7 cells, as well as those in tumor tissues, were suppressed by etodolac. The growth of human dermal lymphatic microvascular endothelial cells was also suppressed by etodolac. Supporting these findings, etodolac also inhibited lymphangiogenesis in a model of chronic aseptic peritonitis, suggesting that COX-2 can enhance lymphangiogenesis in the absence of cancer cells. Our findings suggest that COX-2 inhibitor may be useful for prophylaxis of lymph node metastasis by reducing macrophage-mediated tumor lymphangiogenesis. - TGF-βシグナル伝達と癌 TGF-βシグナル伝達の新しい制御因子としてのId様タンパク質DIP1(TGF-β Signaling and Cancer An Id-like protein, DIP1, as a novel regulator of TGF-β signaling)生島 弘彬; 磯谷 一暢; 古室 暁義; 篠崎 正彦; 宮澤 恵二; 宮園 浩平日本癌学会総会記事 (一社)日本癌学会 66回 409 - 409 0546-0476 2007/08
- Mitsunobu R. Kano; Younsoo Bae; Caname Iwata; Yasuyuki Morishita; Masakazu Yashiro; Masako Oka; Tomoko Fujii; Akiyoshi Komuro; Kunihiko Kiyono; Michio Kaminishi; Kosei Hirakawa; Yasuyoshi Ouchi; Nobuhiro Nishiyama; Kazunori Kataoka; Kohei MiyazonoPROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA NATL ACAD SCIENCES 104 (9) 3460 - 3465 0027-8424 2007/02 [Refereed]
Transforming growth factor (TGF)-beta plays a pivotal role in regulation of progression of cancer through effects on tumor microenvironment as well as on cancer cells. TGF-beta inhibitors have recently been shown to prevent the growth and metastasis of certain cancers. However, there may be adverse effects caused by TGF-beta signaling inhibition, including the induction of cancers by the repression of TGF-beta-mediated growth inhibition. Here, we present an application of a short-acting, small-molecule TGF-beta type I receptor (T beta R-1) inhibitor at a low dose in treating several experimental intractable solid tumors, including pancreatic adenocarcinoma and diffuse-type gastric cancer, characterized by hypovascularity and thick fibrosis in tumor microenvironments. Low-dose T beta R-1 inhibitor altered neither TGF-beta signaling in cancer cells nor the amount of fibrotic components. However, it decreased pericyte coverage of the endothelium without reducing endlothelial area specifically in tumor neovasculature and promoted accumulation of macromolecules, including anticancer nanocarriers, in the tumors. Compared with the absence of T beta R-1 inhibitor, anticancer nanocarriers exhibited potent growth-inhibitory effects on these cancers in the presence of T beta R-1 inhibitor. The use of TiSR-1 inhibitor combined with nanocarriers; may thus be of significant clinical and practical importance in treating intractable solid cancers. - G Kuratomi; A Komuro; K Goto; M Shinozaki; K Miyazawa; K Miyazono; T ImamuraBIOCHEMICAL JOURNAL PORTLAND PRESS LTD 386 (Pt 3) 461 - 470 0264-6021 2005/03 [Refereed]
Inhibitory Smad, Smad7, is a potent inhibitor of TGF-beta (transforming growth factor-beta) superfamily signalling. By binding to activated type I receptors, it prevents the activation of R-Smads (receptor-regulated Smads). To identify new components of the Smad pathway, we performed yeast two-hybrid screening using Smad7 as bait, and identified NEDD4-2 (neural precursor cell expressed, developmentally down-regulated 4-2) as a direct binding partner of Smad7. NEDD4-2 is structurally similar to Smurfs (Smad ubiquitin regulatory factors) 1 and 2, which were identified previously as E3 ubiquitin ligases for R-Smads and TGF-beta superfamily receptors. NEDD4-2 functions like Smurfs I and 2 in that it associates with TGF-beta type I receptor via Smad7, and induces its ubiquitin-dependent degradation. Moreover, NEDD4-2 bound to TGF-beta-specific R-Smads, Smads 2 and 3, in a ligand-dependent manner, and induced degradation of Smad2, but not Smad3. However, in contrast with Smurf2, NEDD4-2 failed to induce ubiquitination of SnoN (Ski-related novel protein N), although NEDD4-2 bound to SnoN via Smad2 more strongly than Smurf2. We showed further that overexpressed NEDD4-2 prevents transcriptional activity induced by TGF-beta and BMP, whereas silencing of the NEDD4-2 gene by siRNA (small interfering RNA) resulted in enhancement of the responsiveness to TGF-beta superfamily cytokines. These data suggest that NEDD4-2 is a member of the Smurf-like C2-WW-HECT (WW is Trp-Trp and HECT is homologous to the E6-accessory protein) type E3 ubiquitin ligases, which negatively regulate TGF-beta superfamily signalling through similar, but not identical, mechanisms to those used by Smurfs. - A Komuro; T Imamura; M Saitoh; Y Yoshida; T Yamori; K Miyazono; K MiyazawaONCOGENE NATURE PUBLISHING GROUP 23 (41) 6914 - 6923 0950-9232 2004/09 [Refereed]
Smad7 negatively regulates transforming growth factor (TGF)-beta superfamily signaling by binding to activated type I receptors, thereby preventing the phosphorylation of receptor-regulated Smads (R-Smads), as well as by recruiting HECT-type E3 ubiquitin ligases to degrade type I receptors through a ubiquitin-dependent mechanism. To elucidate the regulatory mechanisms of TGF-beta signaling, we searched for novel members of proteins that interact with Smad7 using a yeast two-hybrid system. One of the proteins identified was the WW domain-containing protein 1 (WWP1) that is structurally related to Smad ubiquitin regulatory factors (Smurfs), E3 ubiquitin ligases for Smads and TGF-beta superfamily receptors. Using a TGF-beta-responsive reporter in mammalian cells, we found that WWP1 inhibited transcriptional activities induced by TGF-beta. Similar to Smurfs, WWP1 associated with Smad7 and induced its nuclear export, and enhanced binding of Smad7 to TGF-beta type I receptor to cause ubiquitination and degradation of the receptor. Consistent with these results, WWP1 inhibited phosphorylation of Smad2 induced by TGF-beta. WWP1 thus negatively regulates TGF-beta signaling in cooperation with Smad7. However, unlike Smurfs, WWP1 failed to ubiquitinate R-Smads and SnoN. Importantly, WWP1 and Smurfs were expressed in distinct patterns in human tissues and carcinoma cell lines, suggesting unique pathophysiological roles of WWP1 and Smurfs. - D Koinuma; M Shinozaki; A Komuro; K Goto; M Saitoh; A Hanyu; M Ebina; T Nukiwa; K Miyazawa; T Imamura; K MiyazonoEMBO JOURNAL OXFORD UNIV PRESS 22 (24) 6458 - 6470 0261-4189 2003/12 [Refereed]
Arkadia was originally identified as a protein that enhances signalling activity of Nodal and induces mammalian nodes during early embryogenesis; however, the mechanisms by which Arkadia affects transforming growth factor-beta (TGF-beta) superfamily signalling have not been determined. Here we show that Arkadia is widely expressed in mammalian tissues, and that it enhances both TGF-beta and bone morphogenetic protein (BMP) signalling. Arkadia physically interacts with inhibitory Smad, Smad7, and induces its poly-ubiquitination and degradation. In contrast to Smurf1, which interacts with TGF-beta receptor complexes through Smad7 and degrades them, Arkadia fails to associate with TGF-beta receptors. In contrast to Smad7, expression of Arkadia is down-regulated by TGF-beta. Silencing of the Arkadia gene resulted in repression of transcriptional activities induced by TGF-beta and BMP, and accumulation of the Smad7 protein. Arkadia may thus play an important role as an amplifier of TGF-beta superfamily signalling under both physiological and pathological conditions.
MISC
- DASH Suman; 上田健; 古室暁義; 岡田斉 日本癌学会学術総会抄録集(Web) 82nd- 2023
- 古室暁義; 上田健; DASH Suman; 岡田斉 日本癌学会学術総会抄録集(Web) 82nd- 2023
- 本多賢彦; DASH Suman; 古室暁義; 上田健; 岡田斉 日本分子生物学会年会プログラム・要旨集(Web) 46th- 2023
- 古室暁義; 上田健; 岡田斉 日本癌学会学術総会抄録集(Web) 81st- 2022
- オンコメタボライトによる毒性を回避する機構上田 健; 古室 暁義; 天野 恭志; 本多 賢彦; 岡田 斉 日本生化学会大会プログラム・講演要旨集 94回- [P -746] 2021/11
- 炎症性腸疾患関連大腸がんにおけるSirt1-NAD+経路の機能解析天野 恭志; 古室 暁義; 本多 賢彦; 上田 健; 岡田 斉 日本生化学会大会プログラム・講演要旨集 94回- [P -775] 2021/11
- ヒストン脱メチル化酵素UTXの欠損による乳がん細胞の浸潤能はBET阻害剤で抑制される古室 暁義; 上田 健; 岡田 斉 日本癌学会総会記事 80回- [P9 -2] 2021/09
- ヒストン脱メチル化酵素KDM6Aの機能阻害は乳がん悪性化を促進する(Inhibition of histone demethylase KDM6A promotes breast cancer progression)古室 暁義; 上田 健; 岡田 斉 日本癌学会総会記事 78回- E -2084 2019/09
- 8;21転座急性骨髄性白血病におけるエピゲノム調節因子の役割上田 健; 金井 昭教; 古室 暁義; 天野 恭志; 岡田 斉 日本生化学会大会プログラム・講演要旨集 92回- [1P -271] 2019/09
- がん化におけるHLA-B-associated transcript 3(Bat3)/Scytheの役割古室 暁義; 天野 恭志; 上田 健; 岡田 斉 日本生化学会大会プログラム・講演要旨集 92回- [1P -272] 2019/09
- Sirt1-NAD+経路による炎症性腸疾患の抑制機構の解明天野 恭志; 上田 健; 古室 暁義; 岡田 斉 日本生化学会大会プログラム・講演要旨集 92回- [1P -289] 2019/09
- 天野恭志; 上田健; 太田一成; 古室暁義; 岡尚宏; 岡田斉 近畿大学医学雑誌 43- (3-4) 19A -19A 2018/12
- Komuro, Akiyoshi; Ueda, Takeshi; Okada, Hitoshi CANCER SCIENCE 109- 1247 -1247 2018/12
- 急性骨髄性白血病におけるヒストン脱メチル化酵素KDM4Bの役割(Role of histone demethylase KDM4B in acute myeloid leukemia)上田 健; 金井 昭教; 太田 一成; 古室 暁義; 天野 恭志; 岡 尚宏; 岡田 斉 臨床血液 59- (9) 1621 -1621 2018/09
- ヒストン脱メチル化酵素KDM6Aの機能阻害による乳がん悪性化への影響(Effect of inhibition of histone demethylase KDM6A on breast cancer development)古室 暁義; 上田 健; 岡田 斉 日本癌学会総会記事 77回- 2089 -2089 2018/09
- 太田一成; 古室暁義; 上田健; 天野恭志; 岡田斉 日本生化学会大会(Web) 91st- ROMBUNNO.3P‐300 (WEB ONLY) -300] 2018/09
- 上田健; 金井昭教; 太田一成; 古室暁義; 天野恭志; 岡田斉 日本生化学会大会(Web) 91st- ROMBUNNO.1P‐274 (WEB ONLY) -274] 2018/09
- ヒストン脱メチル化酵素KDM6Aの機能阻害による乳がん悪性化への影響(Effect of inhibition of histone demethylase KDM6A on breast cancer development)古室 暁義; 上田 健; 岡田 斉 日本癌学会総会記事 77回- 2089 -2089 2018/09
- 急性骨髄性白血病におけるヒストン脱メチル化酵素KDM4Bの役割(Role of histone demethylase KDM4B in acute myeloid leukemia)上田 健; 金井 昭教; 太田 一成; 古室 暁義; 天野 恭志; 岡 尚宏; 岡田 斉 臨床血液 59- (9) 1621 -1621 2018/09
- 岡尚宏; 天野恭志; 古室暁義; 太田一成; 上田健; 西村俊司; 岡田斉; 赤木將男 日本整形外科学会雑誌 92- (8) S2039 -S2039 2018/08
- 天野恭志; 上田健; 古室暁義; 岡田斉 日本がん分子標的治療学会学術集会プログラム・抄録集 22nd- 96 2018/04
- 上田健; 古室暁義; 天野恭志; 岡田斉 日本がん分子標的治療学会学術集会プログラム・抄録集 22nd- 80 2018/04
- 古室暁義; 上田健; 天野恭志; 岡田斉 日本がん分子標的治療学会学術集会プログラム・抄録集 22nd- 108 2018/04
- Okada, Hitoshi; Komuro, Akiyoshi; Ueda, Takeshi; Ota, Kazushige CANCER SCIENCE 109- 435 -435 2018/01
- 天野恭志; 上田健; 太田一成; 古室暁義; 岡田斉 日本生化学会大会(Web) 91st- ROMBUNNO.2P‐293 (WEB ONLY) -293] 2018
- 太田一成; 古室暁義; 上田健; 岡田斉 日本生化学会大会(Web) 90th- ROMBUNNO.1P‐1148 (WEB ONLY) -1148] 2017/12
- 上田健; 金井昭教; 太田一成; 古室暁義; 岡田斉 日本生化学会大会(Web) 90th- ROMBUNNO.1P‐1020 (WEB ONLY) -1020] 2017/12
- 古室暁義; 太田一成; 上田健; 岡田斉 日本生化学会大会(Web) 90th- ROMBUNNO.2P‐0894 (WEB ONLY) -0894] 2017/12
- ヒストン脱メチル化酵素の乳がん発症・進展における役割岡田 斉; 古室 暁義; 上田 健; 太田 一成 日本癌学会総会記事 76回- E -2004 2017/09
- 岡田斉; 岡田斉; 古室暁義; 上田健 日本がん分子標的治療学会学術集会プログラム・抄録集 21st- 137 2017/05
- K. Ota; K. Tong; K. Goto; S. Tomida; A. Komuro; Z. Wang PLOS ONE 12- (4) 2017/04
- 上田健; 古室暁義; 太田一成; 岡田斉 近畿大学医学雑誌 41- (3-4) 17A -17A 2016/12
- 古室暁義; 太田一成; 上田健; 岡田斉 近畿大学医学雑誌 41- (3-4) 20A -20A 2016/12
- 太田一成; 古室暁義; 上田健; 岡田斉 近畿大学医学雑誌 41- (3-4) 17A -17A 2016/12
- マウスモデルを用いたDNA損傷修復機能抑制による治療関連白血病予防効果の検討岡田 斉; Kit Tong; 太田 一成; 古室 暁義; Koch Anne; 伊藤 彰彦 日本癌学会総会記事 75回- E -1092 2016/10
- 乳がん幹細胞におけるHistone demethylase KDM4bの役割古室 暁義; 太田 一成; 岡田 斉 日本癌学会総会記事 75回- P -1138 2016/10
- 太田一成; TONG Kit I; 後藤幸一郎; 古室暁義; 岡田斉 日本分子生物学会年会プログラム・要旨集(Web) 39th- ROMBUNNO.3P‐0785 (WEB ONLY) 2016
- 古室暁義; 太田一成; 岡田斉 近畿大学医学雑誌 40- (3-4) 17A -17A 2015/12
- 太田一成; 古室暁義; 岡田斉 近畿大学医学雑誌 40- (3-4) 18A -[3P1220] 2015/12
- 岡田斉; 佐相薫葉子; 河津正人; 古室暁義; 太田一成 日本生化学会大会(Web) 88回・38回- [1T17p -01(1P0955)] 2015/12
- 太田一成; TONG Kit I; 後藤幸一郎; 古室暁義; 岡田斉 日本生化学会大会(Web) 88th- (3-4) 3P1220 (WEB ONLY) -18A 2015/12
- 遺伝子プログラム異常による発がん機構と治療標的としての活用 ヒストン脱メチル化酵素、KDM4B/JMJD2B、のがん化過程での役割岡田 斉; 河津 正人; Kit Tong; 佐相 薫葉子; 太田 一成; 古室 暁義 日本癌学会総会記事 74回- CS1 -3 2015/10
- びまん性胃癌 進行、血管新生、TGF-βシグナル伝達(Diffuse-Type Gastric Carcinoma: Progression, Angiogenesis and TGF-β Signaling)古室 暁義; 八代 正和; 岩田 要; 森下 保幸; Johansson Erik; 松元 芳子; 渡辺 亮; 油谷 浩之; 三好 弘之; 清野 邦彦; 白井 陽太郎; 鈴木 洋; 平川 弘聖; 狩野 光伸; 宮園 浩平 日本病理学会会誌 100- (1) 457 -457 2011/03
- 江幡 正悟; Johansson Erik; 片山 量平; 小池 清恵; 渡辺 亮; 星野 佑香梨; 勝野 蓉子; 古室 暁義; 鯉沼 代造; 狩野 光伸; 八代 正和; 平川 弘聖; 油谷 浩幸; 藤田 直也; 宮園 浩平 日本病理学会会誌 100- (1) 457 -457 2011/03
- ヨハンソン エリック; 古室 暁義 細胞科学研究財団助成研究報告集 22- 77 -84 2011
- 狩野光伸; 狩野光伸; 狩野光伸; 岩田要; 古室暁義; 西原広史; 宮園浩平; 宮園浩平 日本病理学会会誌 98- (1) 165 2009/03
- 古室暁義; 岩田要; 八代正和; 森下保幸; JOHANSSON Erik; 松元芳子; 清野邦彦; 白井陽太郎; 鈴木洋; 平川弘聖; 狩野光伸; 宮園浩平 日本病理学会会誌 97- (1) 232 2008/03
- Id様蛋白質DIP1はbHLH転写因子Olig1との相互作用を介してTGF-βシグナル伝達を制御する(An Id-like protein, DIP1, regulates TGF-β signaling through interaction with a bHLH transcription factor, Olig1)生島 弘彬; 磯谷 一暢; 古室 暁義; 篠崎 正彦; Hellman Ulf; 宮澤 恵二; 宮園 浩平 日本生化学会大会・日本分子生物学会年会合同大会講演要旨集 80回・30回- 3T18 -1 2007/11
- 古室暁義; 岩田要; 岡雅子; 森下保幸; 八代正和; 平川弘聖; 狩野光伸; 宮園浩平 日本病理学会会誌 96- (1) 199 2007/02
- 狩野光伸; 岡雅子; 岩田要; 森下保幸; 古室暁義; 宮園浩平 日本病理学会会誌 96- (1) 207 2007/02
- 岡雅子; 森下保幸; 岩田要; 古室暁義; 清野邦彦; 狩野光伸; 宮園浩平 日本病理学会会誌 96- (1) 207 2007/02
- 岩田要; 古室暁義; 岡雅子; 森下保幸; 狩野光伸; 宮園浩平 日本病理学会会誌 96- (1) 207 2007/02
- 岡雅子; 岩田要; 森下保幸; 古室暁義; 清野邦彦; 狩野光伸; 宮園浩平 生化学 4P-0856 2007
- 古室暁義; 岩田要; 岡雅子; 森下保幸; 八代正和; 平川弘聖; 狩野光伸; 宮園浩平 日本癌学会学術総会記事 65th- 36 2006/08
- 岡雅子; 森下保幸; 岩田要; 古室暁義; 狩野光伸; 宮園浩平 日本癌学会学術総会記事 65th- 32 2006/08
- 狩野光伸; 岩田要; BAE Younsoo; 森下保幸; 岡雅子; 古室暁義; 西山伸宏; 片岡一則; 宮園浩平 日本癌学会学術総会記事 65th- 446 2006/08
- 岩田要; 狩野光伸; BAE Yoonsoo; 西山伸宏; 古室暁義; 森下保幸; 岡雅子; 八代正和; 平川弘聖; 片岡一則; 宮園浩平 日本癌学会学術総会記事 65th- 446 2006/08
Research Themes
- 日本学術振興会:科学研究費助成事業Date (from‐to) : 2021/04 -2024/03Author : 古室 暁義Histone demethylaseのUtxはヒストンH3の27番目のリジン(H3K27)のメチル基を取り除き転写を制御する。乳腺組織得意的にUtxを欠損させたマウスと乳がん発症マウス(MMTV-PyMTマウス)の複合変異を持つ乳がん発症マウス (Utx KO; PyMTマウス)では、腫瘍増殖や肺転移が促進し、乳がんの悪性化を起こしていた。Utx KO; PyMTマウス由来の乳がんオルガノイドを樹立して、遺伝子発現やFACS解析を行ったところ、Basal typeの細胞が増えていることが分かった。 マウス乳がん細胞株4T1細胞にLuciferase と赤色蛍光タンパク質であるtdTomato (dimeric Tomato遺伝子のタンデム2量体)を安定発現する細胞株: 4T1-Luc/Tomato細胞を樹立した。この細胞株をBALB/cマウス乳腺に同所移植することで、原発腫瘍および肺転移形成をin vivoイメージングシステムでモニターすることに成功した。Crispr/Cas9 systemによって、4T1-Luc/Tomato細胞のUtxの発現を抑制し、同所移植すると腫瘍増殖が促進し、マウス尾静脈より移植すると肺転移や骨転移も観察された。 転写因子Xは様々ながんで発現が亢進し、浸潤・転移を促進する因子として報告がある。Utx KO; PyMTマウス由来の乳がんオルガノイドでは、転写因子Xの発現増加を伴いながら、I型コラーゲン内の浸潤・増殖が引き起こされているという結果が得られた。Utx KO; PyMT乳がんオルガノイドにおいて、Crispr/Cas9 systemによって転写因子Xの発現を抑制し、マウス尾静脈より移植したところ、肺転移が抑制される結果も得られた。
- Japan Society for the Promotion of Science:Grants-in-Aid for Scientific ResearchDate (from‐to) : 2018/04 -2021/03Author : Okada HitoshiDisruption of the proteostasis network leads to a variety of human diseases including neurodegenerative disorders, metabolic diseases, lysosome diseases, cancer and aging. In this project, we investigated Bat3 functions in vivo using original liver-specific Bat3 deficient mice with special emphasis on metabolic regulation. Histological, biochemical and molecular biological analyses showed that Bat3 deficiency in the liver resulted in liver damages and enhanced ER stress, metabolic stress and inflammation signature. These data suggest that Bat3 deficiency induced dysregulated proteostasis and metabolic stress, which exacerbate liver damage in vivo.
- Japan Society for the Promotion of Science:Grants-in-Aid for Scientific ResearchDate (from‐to) : 2018/04 -2021/03Author : KOMURO AkiyoshiUTX is a histone demethylase that targets di- and tri-methylated histone H3 lysine 27 (H3K27me2/3) and KDM4B is a histone H3K9me2/3 demethylase. To study the effect of histone demethylase UTX and KDM4B loss on breast cancer in vivo, we have generated the mouse mammary tumor virus-polyoma middle T antigen (MMTV-PyMT) model of breast cancer lacking Utx or Kdm4b. We found that Utx deficiency accelerates tumor development and lung metastasis. Furthermore, breast tumor organoids isolated from Utx-deficient MMTV-PyMT mice showed highly invasive phenotype in 3D culture. These results suggested that deletion or decreased expression of UTX may promote human breast cancer progression, implicating clinical relevance of UTX in breast cancer treatment and/or diagnosis. On the other hand, loss of KDM4B suppressed the growth of mouse mammary tumor and prolonged the survival of MMTV-PyMT breast cancer mice. The inhibitor of KDM4B may have the therapeutic effect on breast cancer.
- Japan Society for the Promotion of Science:Grants-in-Aid for Scientific ResearchDate (from‐to) : 2014/04 -2016/03Author : KOMURO AkiyoshiWe attempted to enhance Bone Morphogenetic Protein (BMP) signal in glioma initiating-cells (GICs) by using of siRNA for Smad6 which is the intracellular inhibitor of BMP signal, we observed that BMP4+siSmad6 dramatically inhibited the maintenance of stemness of GICs. Furthermore, we identified several target genes of BMP4+siSmad6 that had the inhibitory effects of the maintenance of stemness of GICs. Additionally, we discovered several novel fusion genes in GICs by using RNA-Seq of this study, and we found that one of fusion genes identified had the transforming potential and high tumor-forming capacity.
- Japan Society for the Promotion of Science:Grants-in-Aid for Scientific ResearchDate (from‐to) : 2012/04 -2014/03Author : KOMURO AKIYOSHITo investigate the effect of TGF-beta family signaling on the stemness of glioma initiating-cells (GICs), we observed that Bone morphogenetic protein 4 (BMP4) had inhibitory effects of the maintenance of stemness of GICs. And we identified novel BMP4 signal target genes in GICs by using gene expression microarray analysis and RNA-seq. Using overexpression or knockdown of these novel BMP4 target genes, we found that these genes were correlated with differentiation and infiltration of GICs. Target therapy of BMP4 signaling target genes may provide a novel strategy for glioma patients.
- 日本学術振興会:科学研究費助成事業Date (from‐to) : 2006 -2007Author : 古室 暁義●スキルス胃癌細胞のTGF-βシグナルを遮断した揚合のin vivoにおける検討 スキルス胃癌は著しい線維化を伴いながら、広範囲にわたるびまん性浸潤を特徴とする、予後不良の癌のひとつである。これらの組織型の原因として、原発巣におけるTGF-βシグナルの充進が考えられている。 そこで我々は、スキルス胃癌の増殖や転移を抑制することを予想して、スキルス胃癌細胞株(OCUM-2MLN)にドミナントネガティブ型TGF-β type II受容体(dnT β RII)を安定発現させ、TGF-βシグナルを抑制した時の腫瘍増殖について、皮下移植モデル・同所移植モデルを用いて検討した。しかし、結果は驚くことに、dnT β RIIによってスキルス胃癌細胞の腫瘍増殖は促進した。このとき、腫瘍血管新生が充進していたとともに、線維化が抑制されていた。また、他のスキルス胃癌細胞株(OCUM-12)においても、dnT β RIIによって腫瘍血管新生が亢進し、腫瘍増殖が促進した。我タは、血管新生の原因の一つとして、血管新生抑制因子であるThrombogpondin(TSP)-1の発現低下が起きていることを見出した。さらに、dnT β RII発現細胞にTSP-1を発現させると、腫瘍増殖が抑制されることが観察された。次に、血管新生阻害剤(Sorafenib)を投与した場合のdnT β RII発現細胞の皮下腫瘍増殖を調べると、増殖を顕著に抑えることができた。同様に、dnT β RIIを発現させた他のスキルス胃癌細胞株(OCUM-12)の皮下腫瘍でも、血管新生阻害剤(Sorafenib)は腫瘍増殖を抑制した。 以上のことから、TGF-βシグナルの破綻した悪性度の高い癌は、血管新生や線維化といった癌微少環境を変化させ増殖・進展を促進しており、これらの悪性度の高い疵において、腫瘍血管新生の阻害が腫瘍増殖の抑制に効果的であることがわかった。現在、Journal of The National Cancer Instituteに投稿中である。